HOME >> BIOLOGY >> NEWS
Key stimulator of colorectal cancer identified

A new research study identifies a molecule that promotes one of the most deadly cancers in humans and reveals the molecular mechanisms underlying the protective effects of nonsteroidal anti-inflammatory drugs (NSAIDS) against the disease. The research, published in the September issue of Cancer Cell, identifies potential targets for future therapeutics aimed at the prevention and treatment of cancer of the colon and rectum.

Colorectal cancer (CRC) is the second most common cause of death due to cancer for men and women in the United States It has been known for some time that NSAIDS and other cyclooxygenase (COX) inhibitors reduce the risk of CRC. However, the exact mechanisms of this protective action are unclear. PGE2 is a metabolite of COX that is elevated in CRC and has been implicated in disease development and progression. Peroxisome proliferator-activated receptor d (PPARd), a regulator of cell survival, has also been linked to CRC. Dr. Raymond N. DuBois from the Department of Medicine at Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center in Nashville, Tennessee and colleagues investigated whether the ability of PGE2 to promote CRC is dependent on PPARd.

The researchers found that PGE2 indirectly activates PPARd via a signaling pathway that promotes cell survival and polyp formation. Polyps are abnormal growths in the colon and rectum that are believed to be an early stage of CRC. In a mouse model system for studying polyp formation, PGE2 treatment induced an increase in the number and size of intestinal polyps. Importantly, this effect of PGE2 was not observed in these mice when they lack PPARd.

"Our results identify PPARd as a critical downstream mediator in PGE2-stimulated promotion of colorectal tumor growth," says Dr. DuBois. "They suggest that PPARd is an important pro-cancer factor in CRC, and that agents which stimulate PPARd may encourage abnormal cell growth in certain populations at risk for CRC.
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
20-Sep-2004


Page: 1 2

Related biology news :

1. Milk consumption and calcium intake associated with lower colorectal cancer risk
2. Researchers identify genetic markers to predict response to chemotherapy for colorectal cancer
3. Study links diabetes and colorectal cancer
4. Drug that cuts off tumors blood supply extends lives of colorectal cancer patients
5. Researchers begin promising new trial to fight colorectal cancer
6. Revised guidelines published for testing for hereditary type of colorectal cancer
7. Mount Sinai School of Medicine conducting clinical trials with gene therapy for colorectal cancer
8. BRCA mutations not associated with colorectal cancer risk, studies suggest
9. BRCA mutations do not increase risk of colorectal cancer
10. Older drug could have exciting new role in treating colorectal cancer
11. New findings suggest colorectal cancer origins are different than previously thought

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2020)... Mass. (PRWEB) , ... August 18, 2020 , ... ... approaches to cell therapy, today announced that the U.S. Food and Drug Administration ... of Sentien’s lead asset, SBI-101, for the treatment of severe COVID-19. Approval of ...
(Date:8/12/2020)... (PRWEB) , ... August 11, 2020 , ... ... subsidiary based in Princeton, NJ, have entered into license agreements with Housey Pharma’s ... development. Both Roche and J&J have annual Research and Development spending in ...
(Date:8/5/2020)... PENSACOLA, Fla. (PRWEB) , ... August 05, 2020 , ... ... to cover two new innovations, CoreText™ and ProText™, making them the first Wharton’s jelly ... a defect using a syringe. The company’s solutions are the first Wharton’s jelly allograft ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... ... , ... “We are thrilled to deliver this new technology to the industry” ... kind on the market and we were pleased that the IFT jury recognized that.” ... ingredients, creating a natural way to extend the shelf life and improve the safety ...
(Date:7/18/2020)... ... July 17, 2020 , ... dicentra ... life sciences and food industries, is pleased to announce that Charles Galea has ... Business Development. , Charles is an accomplished and results-driven sales executive with over ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... announced today that Massachusetts Institute of Technology (MIT) has expanded the company’s ... allows PathSensors to move into the point-of-care diagnostic market, focusing initially on ...
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, ... the hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. ... of Sentien’s lead product, SBI-101. Dr. Nissenson serves as an Emeritus Professor ...
Breaking Biology Technology:
Cached News: